Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
54 hedge funds and large institutions have $57.7M invested in Sio Gene Therapies Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 14 closing their positions.
6% more capital invested
Capital invested by funds: $54.4M → $57.7M (+$3.28M)
1% more call options, than puts
Call options by funds: $614K | Put options by funds: $609K
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
4% less funds holding
Funds holding: 56 → 54 (-2)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.29M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$1.24M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$896K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$539K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$302K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.26M |
| 2 |
SCM
Sio Capital Management
New York
|
-$1.2M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$583K |
| 4 |
CCM
Consonance Capital Management
New York
|
-$538K |
| 5 |
Two Sigma Investments
New York
|
-$454K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Creative Planning
Overland Park,
Kansas
| – | -$148K | -56,728 | Closed |
|
52
UBS Group
Zurich,
Switzerland
| – | -$108K | -41,500 | Closed |
|
|
SM
53
SG3 Management
Dorado,
Puerto Rico
| – | -$91K | -35,000 | Closed |
|
|
CAC
54
Cowen and Company
New York
| – | -$59K | -22,500 | Closed |
|
|
XT
55
XTX Topco
George Town,
Cayman Islands
| – | -$28K | -10,868 | Closed |
|
|
LC
56
Lindbrook Capital
Calabasas,
California
| – | -$24K | -9,099 | Closed |
|
|
IAIM
57
International Assets Investment Management
Orlando,
Florida
| – | -$16K | -6,000 | Closed |
|
|
VFA
58
Valeo Financial Advisors
Carmel,
Indiana
| – | -$13K | -5,000 | Closed |
|
|
TRCT
59
Tower Research Capital (TRC)
New York
| – | -$9.89K | -3,978 | -98% |
|
|
TWA
60
TCI Wealth Advisors
Tucson,
Arizona
| – | -$7K | -2,500 | Closed |
|
61
Credit Agricole
Montrouge Cedex,
France
| – | -$1K | -375 | Closed |
|
62
Bank of America
Charlotte,
North Carolina
| – | -$20 | -8 | -29% |
|
63
Rockefeller Capital Management
New York
| – | +$776 | +312 | New |
|
SIOX Hedge Fund Activity: Q2 2021 in Review
54 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q2 2021, worth a combined $57.7M — up 6% from $54.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of SIOX and 12 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 14 added.
The largest buyer was Vanguard Group, adding an estimated $2.29M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.26M sold.
- 54 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q2 2021, down from 56 in Q1 2021.
- Funds reported $57.7M of Sio Gene Therapies Inc. Common Stock stock for Q2 2021, up 6% quarter-over-quarter.
- 12 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q2 2021 and 14 closed out, a net change of -2 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q2 2021 was Vanguard Group, an estimated $2.29M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q2 2021 was Renaissance Technologies, an estimated $1.26M sold.
Based on aggregated 13F filings for Q2 2021.